ChrysCapital takes 70.68% control of Novartis India to build branded-generics platform
ChrysCapital has acquired Novartis AG’s 70.68% controlling stake in Novartis India, marking its first majority investment in pharma. Vikas Gupta has been appointed CEO and managing director as the company prepares to adopt a new identity.
ChrysCapital acquired a 70.68% controlling stake in Novartis India from Novartis AG, its first majority pharma investment. The firm plans to build an Indian branded-generics platform; Vikas Gupta becomes CEO and managing director as the company adopts a new identity.
Why this matters
No related recent signals were provided. ChrysCapital’s acquisition of control marks a strategic ownership shift for Novartis India and its planned transition toward a branded-generics platform.
Retail-company signals are accelerating, up 314900% quarter over quarter.